Form 4: Sutro Biopharma Executive Awarded Stock Options and Restricted Stock Units
SEC Form 4 Filing
Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, received stock options and restricted stock units (RSUs) on April 4, 2025.
Summary
- On April 4, 2025, Venkatesh Srinivasan, the Chief Technical Operations Officer of Sutro Biopharma, was granted stock options and restricted stock units (RSUs).
- The stock option grants him the right to buy 101,500 shares of common stock at an exercise price of $0.55 per share.
- These options vest monthly starting May 4, 2025, and will be fully vested by April 4, 2029, contingent upon his continued service to the company.
- Additionally, Srinivasan received 94,250 RSUs, each representing a contingent right to receive one share of Sutro Biopharma's common stock upon settlement.
- These RSUs vest annually, beginning on March 2, 2026, with full vesting occurring on March 2, 2029, also subject to his continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating confidence in the executive's role and the company's future. It's a neutral-positive event.
Positives
- The grant of stock options and RSUs aligns Venkatesh Srinivasan's interests with those of Sutro Biopharma's shareholders.
- The vesting schedules incentivize continued service and contribution to the company's success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.
Industry Context
Stock option and RSU grants are common practices in the biopharmaceutical industry to attract, retain, and incentivize key executives. These grants align executive compensation with company performance and shareholder value.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation tools in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely use similar equity-based compensation packages for their executives.
- The vesting schedules (monthly for options, annual for RSUs) are also typical, designed to incentivize long-term commitment.
- The specific amounts of options and RSUs granted would be benchmarked against peer companies of similar size and stage of development as Sutro Biopharma.
Stakeholder Impact
- Shareholders may view the grants positively as they align executive interests with company performance.
- Employees may see it as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/04/2025 | Date of the transaction: grant of stock options and RSUs. |
| 05/04/2025 | First monthly vesting date for the stock options. |
| 03/02/2026 | First annual vesting date for the RSUs. |
| 04/04/2029 | Date when the stock options are fully vested. |
| 03/02/2029 | Date when the RSUs are fully vested. |
| 04/08/2025 | Date of the Form 4 filing. |
Keywords
Sutro Biopharma, Stock Options, Restricted Stock Units, RSUs, Vesting, Executive Compensation, Form 4, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.